03:42 PM EST - Valeant Pharmaceuticals International, Inc. : announced that its subsidiary, Biovail Laboratories International SRL, has signed agreements to acquire all U.S. and Canadian rights to non-ophthalmic topical formulations of Zovirax(R) from GlaxoSmithKline for $300 million. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $0.56 at $38.86.
